Drug intelligence / Profile preview

buqi oral liquid

Development stage: Unknown
Lead developer: Anhui Joyfar Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Buqi Oral Liquid (补气口服液) is an approved Traditional Chinese Medicine (TCM) developed and manufactured by Anhui Joyfar Pharmaceutical, a subsidiary of Hunan Jingfeng Pharmaceutical. It is primarily indicated for the treatment of Qi deficiency, a state in TCM characterized by fatigue, shortness of breath, and weakened immunity. The formulation is an oral liquid typically derived from the extract of *Astragalus membranaceus* (Huangqi), which is recognized for its tonifying and immunomodulatory properties. As a TCM product, it functions as a general health tonic and immune support agent; however, no specific molecular targets have been disclosed for its mechanism of action.

Brand names: 补气口服液
Other names: Buqi Oral Liquid

Beyond the preview

Go deeper on buqi oral liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on buqi oral liquid.

Explore the full profile